J&J Unit Escapes Antitrust Suit Over Prostate Cancer Drug
A New Jersey federal judge has dismissed an antitrust complaint accusing a Johnson & Johnson unit of launching sham patent litigation in order to delay generic competition from its blockbuster prostate...To view the full article, register now.
Already a subscriber? Click here to view full article